Navigation Links
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Date:6/11/2009

SAN FRANCISCO, June 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's disease.

The international, double-blind, placebo-controlled, pivotal Phase 3 study enrolled 598 patients, exceeding the enrollment target of 525 patients. More than 40 percent of the patients enrolled were in the United States. The six-month study is evaluating the effect of dimebon on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change plus caregiver interview (CIBIC-plus) -- the two endpoints have historically been accepted by the U.S. Food and Drug Administration (FDA) to support registration of currently approved drugs for mild-to-moderate Alzheimer's disease.

"Completion of patient enrollment in this second pivotal trial moves us closer to our goal of submitting a marketing application to the FDA and bringing dimebon to market for the many Alzheimer's patients suffering from this devastating disease," said Lynn Seely, M.D., chief medical officer of Medivation. "We are gratified by the strong interest in this trial as indicated by our exceeding the enrollment goal. Together with our partner Pfizer, we are executing a comprehensive clinical plan to support an NDA filing, currently targeted for 2011, with a broad and differentiated label for dimebon in Alzheimer's disease. We are also conducting a Phase 3 safety study, which will provide us and Pfizer the opportunity to seek marketing approval earlier if results of the CONNECTION study confirm our previously completed first pivotal study, which was published in the Lancet last year."


'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Pricing of Public Offering
2. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
3. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
4. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
5. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
8. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
10. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
11. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... MD (PRWEB) July 29, 2014 ... a vaccine pioneer in the biotechnology industry, announced ... Newport Coast Securities, Inc. to explore financing opportunities ... LAMP-vax technology, a breakthrough vaccine platform with the ... market. The company exclusively licensed the well-established LAMP ...
(Date:7/29/2014)... ST. LOUIS , July 29, 2014  Sigma-Aldrich ... global water and energy use, increased its investment in ... community service around the world last year, the Company ... Report: What if Science Changed the World? ... has earned several honors for being a responsible corporate ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... 2014 Eppendorf Centrifuge 5427 R ... Eppendorf 5427 R is geared towards high-end applications like ... is targeted towards work requiring high sample throughput. Pipette.com ... it compliments their extensive 16, 48, and 64 multichannel ... tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... 22 Fred Hutchinson Cancer Research Center,s,stem-cell transplant ... was,one of only two transplant programs nationwide that ... donor transplants, according,to an independent report that assessed ... The Center for International Blood ...
... in Genetic Engineering News for delivering the promise of safety without ... ... (PRWEB) January 22, 2009 -- InVitria,s product line was featured in ... 15, 2009 pp 32-34). The article, entitled Culture Media Underlies ...
... SAN DIEGO, Jan. 22 Axikin Pharmaceuticals, Inc., ... small molecule therapeutics for respiratory and inflammatory diseases, ... its Series A stock. The financing was ... Additional investors include Mitsui & Co. Venture ...
Cached Biology Technology:Transplant Program Tops in Expected One-Year Survival Rate 2InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication 2Axikin Pharmaceuticals Spins out of Actimis 2Axikin Pharmaceuticals Spins out of Actimis 3
(Date:7/29/2014)... San Francisco is the first to show that while ... cellular aging, these negative effects may be reduced by ... , "The study participants who exercised, slept well and ... who didn,t maintain healthy lifestyles, even when they had ... PhD, assistant professor in the department of psychiatry at ...
(Date:7/28/2014)... a circulatory problem of the legs called peripheral vascular ... surgery in serious cases. This disease can lead to ... , At The University of Texas Health Science Center ... preventative treatment in a mouse model of the disease ... Their proof-of-concept study appears in the journal Cell ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... N.Y. Despite the fact that congenital heart ... the United States, pediatric cardiology receives relatively little attention ... volume entitled My Heart vs. the Real World ... Through striking black-and-white photographs and interviews with CHD ...
... risk by 72% in male smokers who had high ... effect on those who had low dietary vitamin C ... Journal of Nutrition. Previous studies had suggested that ... studies vitamin E seemed to protect against various infections. ...
... straight line may be the shortest distance between two ... path to follow. Thats particularly true when terrain ... have developed a mathematical model showing that a zigzag ... go up or down steep slopes. I think ...
Cached Biology News:New book gives a human face to children with congenital heart disease 2In the race to the top, zigzagging is more efficient than a straight line 2
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: